Phase I Dose Escalation trials in cancer immunotherapy: Modifying the Bayesian Logistic Regression Model for Cytokine Release Syndrome
Chapman-Rounds, M.; Pereira, M.
Show abstract
We extend Bayesian Logistic Regression to model the dose-toxicity relationship in the setting of phase I dose-escalation/ dose-finding trials for cancer immunotherapies. Immunotherapy drugs are associated with Cytokine Release Syn-drome, a systemic immune system reaction that can be mitigated when initial lower doses of the drug are administered to generate immune tolerance. This changes the classic dose-finding problem of determining an optimal safe dose, to a more complex problem where the search is for both the optimal safe dose and the dose regimen that allows patients to quickly and safely reach that dose without CRS. As part of solving this methodological challenge, we show how to jointly model CRS and non-CRS toxicities, which have distinct mechanisms, while controlling for the overall toxicity rate to make dose-escalation decisions.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Chemotherapy-Induced Cachexia and Model-Informed Dosing to Preserve Lean Mass in Cancer Treatment 94%
- Combination Treatment Optimization Using aPan-Cancer Pathway Model 94%
- A regularized functional regression model enabling transcriptome-wide dosage-dependent association study of cancer drug response 92%
Similar papers in this journal
- Two-Stage Multivariate Mendelian Randomization on Multiple Outcomes with Mixed Distributions 92%
- Health Utility Adjusted Survival: a Composite Endpoint for Clinical Trial Designs 91%
- Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic 90%
Similar papers in this journal
Similar papers in this journal
- A scaling approach to estimate the COVID-19 infection fatality ratio from incomplete data 92%
- Applying Historical Data in a Nonlinear Mixed-Effects Model Can Reduce the Number of Control Rats Required for Calculation of the Relative Potency of Insulin Analogues 92%
- A Bayesian Susceptible-Infectious-Hospitalized-Ventilated-Recovered Model to Predict Demand for COVID-19 Inpatient Care in a Large Healthcare System 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.